3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
89
Leukemia
68
Precursor Cell Lymphoblastic Leukemia-Lymphoma
36
Lymphoma
26
Leukemia, Erythroblastic, Acute
19
Leukemia, Myelomonocytic, Acute
18
Leukemia, Monocytic, Acute
18
Leukemia, Megakaryoblastic, Acute
18
Congenital Abnormalities
13
Burkitt Lymphoma
13
Lymphoma, Large B-Cell, Diffuse
12
Myelodysplastic Syndromes
10
Lymphoma, Non-Hodgkin
10
Anemia, Refractory, with Excess of Blasts
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Lymphoma, Follicular
6
Leukemia, Myelomonocytic, Chronic
6
Leukemia, Myeloid, Chronic-Phase
6
Leukemia, Eosinophilic, Acute
6
Recurrence
5
Myeloproliferative Disorders
5
Lymphoma, Large-Cell, Immunoblastic
5
Leukemia, Promyelocytic, Acute
5
Leukemia, Biphenotypic, Acute
5
Leukemia, Basophilic, Acute
5
Hodgkin Disease
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasms
4
Myelodysplastic-Myeloproliferative Diseases
4
Multiple Myeloma
4
Interventions
Cyclophosphamide
3
Epirubicin
2
Docetaxel
2
Carboplatin
2
Capecitabine
2
Azacitidine
2
venetoclax
1
tegafur-gimeracil-oteracil
1
taxane
1
sargramostim
1
ruxolitinib
1
rucaparib
1
pirarubicin
1
pertuzumab
1
pembrolizumab
1
olaparib
1
cc-486
1
Trastuzumab
1
Thalidomide
1
Radiotherapy
1
Radiation
1
Platinum
1
Paclitaxel
1
Oxaliplatin
1
Observation
1
Nivolumab
1
Monatide (IMS 3015)
1
Methotrexate
1
Magnetic Resonance Imaging
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Pathologic Complete Response
×
Cytarabine
×
Clear all
NCT04229979
2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3
Active not recruiting
127 enrolled